Prosecution Insights
Last updated: October 25, 2026
Application No. 17/796,532

CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES

Non-Final OA §DOUBLEPATENT
Filed
Jul 29, 2022
Priority
Jan 31, 2020 — EU 20382063.4 +1 more
Examiner
CHONG, KIMBERLY
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tyris Therapeutics S L
OA Round
2 (Non-Final)
72%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
1088 granted / 1504 resolved
+12.3% vs TC avg
Moderate +13% lift
Without
With
+13.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
50 currently pending
Career history
1568
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1504 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Application/Amendment/Claims Applicant's response filed 07/06/2026 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 03/04/2026 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. With entry of the amendment filed on 07/06/2026, claims 1, 9, 10, 12, 15, 23-27 and 30-33 are pending in the application. Claims 25 is rejoined and new claims 30-33 ae within the scope of the elected invention and are rejoined. SEQ ID Nos. 7, 9, 10 and 13 are free of the prior art and are not obvious in view of the prior art as hairpin adapters as in claim 1. The 112(a) and Double-Patenting rejection against co-pending Application No. 17,796,596 (App596) is withdrawn in response to claim amendments. Withdrawn Rejections Any rejection not reiterated in this Office Action is hereby withdrawn. New Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 9, 10, 12, 15, 23-27 and 30-33 are provisionally rejected under the judicially created doctrine of double patenting over claims 1-29 of co-pending Application No. 19,551,392 (App392). This is a provisional double patenting rejection since the conflicting claims have not yet been patented. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the patent are drawn to patently indistinguishable subject matter. Claims 1-29 of App392 are drawn to a closed linear DNA with modifications of the hairpin adaptors as instantly claimed and is not patentably distinct from the instantly claimed closed linear DNA. This is a provisional obviousness-type double patenting rejection. Reasons for Indication of Claims Free of the Prior Art Claims 1, 9, 10, 12, 15, 23-27 and 30-33 are not found in the prior or made obvious by the prior art. Metzker et al. (WO 2015/157747 of record cited on IDS filed 09/06/2022) teach a closed linear DNA molecule comprising hairpin loops at each end of a double stranded sequence as claimed. Metzker discloses that "[m]odified nucleotides may be substituted to alter the stability of the double-stranded stem region." See paragraph [00065] and does not teach or suggest the presently claimed clDNA with modified nucleotides located in each single stranded loop of the hairpin. It would The prior art of Serantes et al., Heinrich et al. and Walters et al (of record 892 03/04/2026) teach double stranded DNA molecules with hairpin adapter sequences attached at the ends. The prior art of Metzker et al. does not make it obvious to modify the hairpin adaptors. Furthermore, the claimed clDNA has the advantage of increased expression of an encoded product as shown in Figs 6 and 8 (Examples 2 and Table 3). The prior art does not teach or make obvious modifying the single stranded hairpin adaptors with the claimed nucleotides wherein the clDNA has increased expression of encoded proteins. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong at (571)272-3111. The examiner can normally be reached Monday thru Friday between M-F 8:00am-4:30pm. If attempts to reach the examiner by telephone are unsuccessful please contact the SPE for 1636 Neil Hammell at 571-272-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO’s Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO’s PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. /KIMBERLY CHONG/ Primary Examiner Art Unit 1636
Read full office action

Prosecution Timeline

Jul 29, 2022
Application Filed
Mar 04, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Jul 06, 2026
Response Filed
Oct 14, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767947
CHANNEL MODULATORS
4y 2m to grant Granted Oct 20, 2026
Patent 12766163
METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING TUBB2B
3y 9m to grant Granted Oct 20, 2026
Patent 12760309
Anti-CD3 Aptamers for Use in Cell Targeting and Labeling
4y 8m to grant Granted Oct 13, 2026
Patent 12760308
COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSION
4y 0m to grant Granted Oct 13, 2026
Patent 12758571
Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors
3y 12m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
72%
Grant Probability
85%
With Interview (+13.1%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1504 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month